Hims & Hers shares drop on doubts over weight-loss business forecast
Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's ...
Novo Nordisk Stock Rallies on Weight-Loss Retreat by Hims & Hers
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...
Lilly launches higher dose vials of weight-loss drug for $150 less than injector pen
Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at ...
devdiscourse43m
Eli Lilly Slashes Prices on Weight-Loss Drug to Boost Demand
Eli Lilly has reduced the price of its weight-loss drug Zepbound, offering higher doses in vials at a discount to boost demand and compete with Novo Nordisk's Wegovy. The price adjustment aims to ease ...
Hims & Hers flags possible halt to compounded weight-loss drug sales; shares slump
Investing.com - Hims&Hers (NYSE:HIMS) said on Monday that it may stop selling legal copies of a popular weight-loss drug made by Denmark's Novo Nordisk (NYSE:NVO), sending shares in the U.S.
pharmaphorum43m
Lilly launches discounted high-strength Zepbound vials in US
Lilly recently revised its revenue forecast for 2024 after seeing weaker-than-expected growth for Zepbound and diabetes brand ...
pharmaphorum46m
Lilly launches discounted Zepbound vials in US
Lilly recently revised its revenue forecast for 2024 after seeing weaker-than-expected growth for Zepbound and diabetes brand ...